Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Rheumatology
•
Crystal Arthritis
•
Primary Care
When would you recommend uric acid-lowering therapy for a patient with asymptomatic hyperuricemia without comorbidities but with family history of gout?
Related Questions
Do you still consider the use of pegloticase in someone with substantial tophaceous burden despite optimal uric acid levels?
Do you prefer allopurinol or febuxostat for patients with chronic kidney disease who are receiving treatment for asymptomatic hyperuricemia?
Would you use febuxostat for an African-American patient with gout and previous cardiovascular events (stroke, MI) who tested positive for HLA-B*5801?
Is there any expanded diagnostic workup that you pursue for a young female patient with gout?
If a patient who has tolerated allopurinol for a prolonged period of time is subsequently found to be positive for the HLA-B*58:01 gene, how would you manage urate-lowering therapy thereafter?
Do you avoid hyaluronic acid injections in patients with chondrocalcinosis on imaging?
Do you prefer using losartan in your patients with hypertension and gout due to its uricosuric effects?
Do you delay pegloticase in a patient with an active gout flare?
Do you routinely recommend barbotage for calcific tendinopathy of the shoulder?
How do you use P1NP in your clinical practice to guide management of osteoporosis?
